BackTable Urology

Ep. 93 Management of Advanced Prostate Cancer for the Urologist with Dr. Rana McKay


Listen Later

On this episode of BackTable Urology, Dr. Aditya Bagrodia and Dr. Rana McKay, a medical oncologist at UC San Diego, discuss guidelines and advances in prostate cancer treatment.


---


CHECK OUT OUR SPONSOR


Veracyte

https://www.veracyte.com/decipher


---


EARN CME


Reflect on how this Podcast applies to your day-to-day and earn free AMA PRA Category 1 CMEs: https://earnc.me/B9kR7B


---


SHOW NOTES


First, they define three types of prostate cancer. Metastatic castration-sensitive disease refers to patients with metastatic cancer who have low testosterone levels because of androgen deprivation therapy (ADT). Nonmetastatic castration-resistant disease is nonmetastatic cancer with testosterone levels unresponsive to ADT. This category is harder to define as the classification varies based on imaging modality. Finally, metastatic castration-resistant disease is the most lethal type of prostate cancer, as there is an unmet need in developing therapeutics for these patients. Traditionally, the castrate level is defined as a testosterone level <50 ng/dL.


Then, the doctors discuss different types of ADT, which include GnRH agonists, GnRH antagonists, and anti-androgen receptor medications. When explaining ADT to her patients, Dr. McKay always identifies the class of the agent and common side effects (i.e.- bone composition changes, metabolic changes, and mood and libido changes). Dr. McKay notes that she has observed many patients who have had success with ADT and shares lifestyle tips that she recommends to mitigate the side effects of ADT.


Next, the doctors summarize treatment options for different types of prostate cancer patients, including those with de novo metastatic prostate cancer, metastatic hormone sensitive disease, biochemically recurrent disease, and chemotherapy naive patients. In addition, they reflect on past landmark trials and current prospective trials about different combinations of therapies. They end the episode by discussing lutetium-177 as a new therapy for prostate cancer.


---


RESOURCES


Veracyte Decipher Prostate Genomic Classifier

https://www.veracyte.com/diagnostics/prostate-cancer


Prostate Cancer Foundation

https://www.pcf.org/


Zero Prostate Cancer

https://zerocancer.org/

...more
View all episodesView all episodes
Download on the App Store

BackTable UrologyBy BackTable

  • 4.8
  • 4.8
  • 4.8
  • 4.8
  • 4.8

4.8

49 ratings


More shows like BackTable Urology

View all
Behind The Knife: The Surgery Podcast by Behind The Knife: The Surgery Podcast

Behind The Knife: The Surgery Podcast

1,300 Listeners

White Coat Investor Podcast by Dr. Jim Dahle of the White Coat Investor

White Coat Investor Podcast

2,430 Listeners

The Curbsiders Internal Medicine Podcast by The Curbsiders Internal Medicine Podcast

The Curbsiders Internal Medicine Podcast

3,332 Listeners

The Peter Attia Drive by Peter Attia, MD

The Peter Attia Drive

7,910 Listeners

Post Reports by The Washington Post

Post Reports

5,428 Listeners

Money Meets Medicine by Doctor Podcast Network, Jimmy Turner MD

Money Meets Medicine

219 Listeners

The Passive Income MD Podcast by Peter Kim, MD

The Passive Income MD Podcast

279 Listeners

Urology Coding and Reimbursement Podcast by Mark Painter, Scott Painter and Dr. Ray Painter

Urology Coding and Reimbursement Podcast

14 Listeners

The Ezra Klein Show by New York Times Opinion

The Ezra Klein Show

15,220 Listeners

EAU Podcasts by European Association of Urology

EAU Podcasts

3 Listeners

Urology Audio Guidelines by Nicolas Seranio, MD

Urology Audio Guidelines

4 Listeners

The Weekly Show with Jon Stewart by Comedy Central

The Weekly Show with Jon Stewart

10,508 Listeners

AUA Leadership and Business by American Urological Association

AUA Leadership and Business

2 Listeners

Urology Times Podcasts by Urology Times

Urology Times Podcasts

0 Listeners

Point Me To First Class by Devon Gimbel MD

Point Me To First Class

1,144 Listeners